Finnish firm, Nova sign pact

September 18, 1990

Baltimore-based Nova Pharmaceutical Corp. said yesterday that it has signed an agreement with Finland-based Orion Corp. Farmos for exclusive marketing rights in Scandinavian countries to the gliadel implant, a treatment for primary brain cancer that Nova is developing.

In a news release, Nova said Orion will conduct supplemental clinical trials of the product and will seek marketing approval in Finland, Denmark, Norway and Sweden. After approval by government regulators, Nova will manufacture the product for sale by Orion.

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.